207 related articles for article (PubMed ID: 26049669)
1. A standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer.
Mu K; Li L; Yang Q; Yun H; Kharaziha P; Ye DW; Auer G; Lagercrantz SB; Zetterberg A
Ann Diagn Pathol; 2015 Aug; 19(4):243-8. PubMed ID: 26049669
[TBL] [Abstract][Full Text] [Related]
2. A Comparison of the Hot Spot and the Average Cancer Cell Counting Methods and the Optimal Cutoff Point of the Ki-67 Index for Luminal Type Breast Cancer.
Arima N; Nishimura R; Osako T; Nishiyama Y; Fujisue M; Okumura Y; Nakano M; Tashima R; Toyozumi Y
Oncology; 2016; 90(1):43-50. PubMed ID: 26613521
[TBL] [Abstract][Full Text] [Related]
3. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases.
Tökés AM; Szász AM; Geszti F; Lukács LV; Kenessey I; Turányi E; Meggyesházi N; Molnár IA; Fillinger J; Soltész I; Bálint K; Hanzély Z; Arató G; Szendröi M; Kulka J
J Clin Pathol; 2015 Apr; 68(4):274-82. PubMed ID: 25595275
[TBL] [Abstract][Full Text] [Related]
4. The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value.
Cho U; Kim HE; Oh WJ; Yeo MK; Song BJ; Lee A
Appl Immunohistochem Mol Morphol; 2016 Mar; 24(3):159-66. PubMed ID: 25789536
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract][Full Text] [Related]
6. A comparison of Ki-67 counting methods in luminal Breast Cancer: The Average Method vs. the Hot Spot Method.
Jang MH; Kim HJ; Chung YR; Lee Y; Park SY
PLoS One; 2017; 12(2):e0172031. PubMed ID: 28187177
[TBL] [Abstract][Full Text] [Related]
7. [Comparative studies on the biological significance of the marker for proliferation Ki-67-Antigen and PCNA in primary ovarian carcinoma].
Reitmaier M; Rudlowski C; Biesterfeld S; Rath W; Schröder W
Zentralbl Gynakol; 2000; 122(7):361-7. PubMed ID: 10951706
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.
Aziz S; Wik E; Knutsvik G; Klingen TA; Chen Y; Davidsen B; Aas H; Aas T; Akslen LA
PLoS One; 2016; 11(3):e0150979. PubMed ID: 26954367
[TBL] [Abstract][Full Text] [Related]
9. [Ki-67 and cyclin A--prognostic factors in breast cancer. Time to introduce proliferation markers in clinical routine].
Ahlin C; Fernö M; Amini RM; Tolockiene E; Blomqvist C; Bergh J; Fjällskog ML
Lakartidningen; 2010 Mar 10-16; 107(10):672-5. PubMed ID: 20402250
[No Abstract] [Full Text] [Related]
10. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
[TBL] [Abstract][Full Text] [Related]
11. Relationship between postoperative recurrence and expression of cyclin E, p27, and Ki-67 in non-small cell lung cancer without lymph node metastases.
Takahashi S; Kamata Y; Tamo W; Koyanagi M; Hatanaka R; Yamada Y; Tsushima T; Takaya S; Fukuda I
Int J Clin Oncol; 2002 Dec; 7(6):349-55. PubMed ID: 12494250
[TBL] [Abstract][Full Text] [Related]
12. Changes and predictive and prognostic value of the mitotic index, Ki-67, cyclin D1, and cyclo-oxygenase-2 in 710 operable breast cancer patients treated with neoadjuvant chemotherapy.
Penault-Llorca F; Abrial C; Raoelfils I; Chollet P; Cayre A; Mouret-Reynier MA; Thivat E; Mishellany F; Gimbergues P; Durando X
Oncologist; 2008 Dec; 13(12):1235-45. PubMed ID: 19091781
[TBL] [Abstract][Full Text] [Related]
13. The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; van de Vijver MJ
Eur J Surg Oncol; 1999 Aug; 25(4):356-63. PubMed ID: 10419704
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
15. The impact of cell proliferation markers and p53 mutation status on prognosis of non-metastatic colon cancer.
Demir L; Ekinci N; Erten C; Somali I; Can A; Dirican A; Cokmert S; Bayoglu V; Akyol M; Kucukzeybek Y; Alacacioglu A; Tarhan MO
J Surg Oncol; 2014 Jun; 109(7):665-75. PubMed ID: 24464927
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma: a comparison with cyclins A and B1, Ki-67, proliferating cell nuclear antigen, and p34cdc2.
Kallakury BV; Sheehan CE; Rhee SJ; Fisher HA; Kaufman RP; Rifkin MD; Ross JS
Cancer; 1999 Apr; 85(7):1569-76. PubMed ID: 10193948
[TBL] [Abstract][Full Text] [Related]
17. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values?
Ahlin C; Aaltonen K; Amini RM; Nevanlinna H; Fjällskog ML; Blomqvist C
Histopathology; 2007 Oct; 51(4):491-8. PubMed ID: 17711446
[TBL] [Abstract][Full Text] [Related]
18. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
[TBL] [Abstract][Full Text] [Related]
19. Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.
Lundgren C; Ahlin C; Holmberg L; Amini RM; Fjällskog ML; Blomqvist C
Acta Oncol; 2015 Apr; 54(4):538-44. PubMed ID: 25327158
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis.
Miglietta L; Vanella P; Canobbio L; Naso C; Cerisola N; Meszaros P; Parodi MA; Morabito F
Oncology; 2010; 79(3-4):255-61. PubMed ID: 21372600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
